Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating for Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $26.
September 06, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating for Phathom Pharmaceuticals and maintained a price target of $26, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $26 price target by a reputable analyst suggests positive sentiment and confidence in Phathom Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100